Precision Medicine Fuels $85B Growth in Cancer Biopsy Market

[thorat Ketan]

The global Cancer Biopsy Market is on a transformative growth trajectory, projected to rise from USD 28.12 billion in 2023 to an impressive USD 85.03 billion by 2032, advancing at a compound annual growth rate (CAGR) of 13.0% from 2024 to 2032. This surge reflects significant progress in early cancer detection, rising cancer prevalence, and major technological innovations in biopsy procedures.

Biopsies play a critical role in cancer diagnosis and treatment planning, helping clinicians confirm malignancy, determine cancer stage, and guide personalized therapies. As precision medicine and minimally invasive diagnostics continue to gain prominence, the demand for advanced biopsy techniques is witnessing exponential growth across global healthcare ecosystems.

Get Free Sample Report on Cancer Biopsy Market  

https://www.snsinsider.com/sample-request/1759

Market Drivers

Rising Global Cancer Incidence

One of the primary drivers of the cancer biopsy market is the rising incidence of various cancer types worldwide. According to the World Health Organization (WHO), cancer is among the leading causes of death globally, accounting for nearly 10 million deaths in 2022. The increasing burden of cancer across both developed and developing nations has propelled the need for more accurate, accessible, and early-stage diagnostic tools.

Technological Advancements in Biopsy Techniques

Advances in biopsy technology have dramatically improved diagnostic accuracy and patient outcomes. Liquid biopsy, for instance, is gaining widespread traction due to its non-invasive nature and its ability to detect cancer through a simple blood sample. It provides real-time insights into tumor genetics, enabling faster decision-making and personalized treatment approaches.

Additionally, image-guided biopsies, robotic-assisted procedures, and AI-integrated pathology tools are transforming traditional methods, allowing earlier detection, reduced recovery times, and enhanced procedural efficiency.

Shift Toward Personalized Medicine

As oncology moves toward individualized therapy, biopsies are no longer just diagnostic tools—they're essential for understanding tumor genomics. Tissue and liquid biopsies provide data to inform immunotherapy decisions, monitor disease progression, and assess treatment resistance. The growing adoption of genomic profiling and molecular diagnostics is fueling biopsy demand in both clinical and research settings.

Key Segmentation

By Product

• Instrument
• Kits and Consumables
• Services

By Type

• Tissue Biopsies
  1. Needle Biopsies
  2. Surgical Biopsies
• Liquid Biopsies
  1. Fine Needle Aspiration (FNA)
  2. Core Needle Biopsy (CNB)
• Others

By Application

• Breast Cancer
• Colorectal Cancer
• Cervical Cancers
• Lung Cancers
• Prostate Cancers
• Skin Cancers
• Blood Cancers
• Kidney Cancers
• Liver Cancers
• Pancreatic Cancers
• Ovarian Cancers
• Others

 

Key Players

• QIAGEN
• Illumina, Inc.
• ANGLE plc
• Hologic, Inc.
• Biocept, Inc.
• BD (Becton, Dickinson, and Company)
• Myriad Genetics, Inc.
• Thermo Fisher Scientific, Inc.
• Genesystems, Inc. (Genesys Biolabs)
• Danaher
• F. Hoffmann-La Roche Ltd.
• Lucence Health Inc.
• GRAIL, Inc.
• Natera, Inc.
• Personalis Inc.
• Guardant Health Inc.
• Exact Sciences Corporation
• Oncimmune
• Epigenomics AG
• HelioHealth (Laboratory for Advanced Medicine)
• Freenome Holdings, Inc.
• Biodesix (Integrated Diagnostics)
• Chronix Biomedical, Inc.
• Personal Genome Diagnostics Inc. and others.

Market Outlook

The cancer biopsy market is expected to experience unprecedented growth throughout the forecast period. Factors such as the push toward early detection, integration of AI in diagnostics, and growing adoption of non-invasive biopsy solutions will redefine how cancer is diagnosed and monitored.

Moreover, the increasing trend of home-based testing kits, combined with mobile diagnostics and cloud-based data sharing platforms, will bring biopsy diagnostics closer to patients than ever before. These trends, aligned with rising healthcare digitization, will shape the future of cancer diagnosis and treatment.

Conclusion

With the global burden of cancer continuing to rise and the evolution of advanced diagnostic technologies, the cancer biopsy market is poised for transformative growth. From traditional needle biopsies to cutting-edge liquid and AI-driven solutions, the landscape is evolving to offer faster, safer, and more accurate diagnostics—making personalized cancer care a global reality.

The forecasted growth from USD 28.12 billion in 2023 to USD 85.03 billion by 2032 is not just a reflection of market potential but a symbol of medical innovation and hope in the global fight against cancer.

 About US

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:

Jagney Dave - Vice President of Client Engagement

Phone: [phone] (US) | [phone] (UK)